[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340469-105":59,"doc-detail-340469-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","variability-of-quality-of-life-measurements-and-reporting-in-randomised-controlled-trials-of-pancreatic-cancer-a-systematic-review","Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer - a systematic review","","This systematic review evaluates the methodologies used in pancreatic cancer randomized controlled trials that measured quality of life. It synthesizes study design choices, including the type of quality-of-life instrument, assessment timing and survey frequency, survey completion rates over time, analytic approaches, and reported patient demographics. PubMed and ClinicalTrials.gov were searched from inception to 21 March 2023, including only phase III trials with quality-of-life measurement. Forty-eight of 54 trials assessed quality of life were excluded or not eligible, while 24 trials involving 11,229 patients measured quality of life.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/variability-of-quality-of-life-measurements-and-reporting-in-randomised-controlled-trials-of-pancreatic-cancer-a-systematic-review/340469/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/variability-of-quality-of-life-measurements-and-reporting-in-randomised-controlled-trials-of-pancreatic-cancer-a-systematic-review/340469.png","ImageObject",300,407,{"name":92,"@type":93},"Seraphina","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the systematic review evaluate in pancreatic cancer RCTs?","Question",{"text":113,"@type":114},"It evaluates the methodology used to measure quality of life in pancreatic cancer randomized controlled trials, focusing on instrument type, assessment frequency and duration, survey compliance, and reporting practices.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which studies were included or excluded?",{"text":118,"@type":114},"Only phase III pancreatic cancer RCTs measuring quality of life were included. Studies were excluded if quality of life was not measured, if they were phase I/II, if they were in the second-line setting, or if they were unavailable in English.",{"name":120,"@type":111,"acceptedAnswer":121},"What were the main findings about variability in quality-of-life measurement?",{"text":122,"@type":114},"There was significant variability in the timing, methods, and reporting of quality-of-life assessments. Most trials assessed quality of life until disease progression or death, and only a small proportion reported significant quality-of-life improvements between treatment arms.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},340469,1790641630,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Open access Original research  \nTo cite: Tushoski-Alemán GW, Crespin AJ, Oguejiofor CJ, et al. Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer: a systematic review. BMJ Open 2024;14:e083696 . doi:10 . 1136/ bmjopen-2023-083696  \n► Prepublication history and additional supplemental material for this paper are available online. To view these files, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[bmjopen-2023-083696](bmjopen-2023-083696)) .  \nAJC and CJO contributed equally.  \nReceived 26 December 2023 Accepted 11 October 2024  \n© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.  \nDepartment of Surgery, University of Florida, Gainesville, Florida, USA  \nCorrespondence to  \nDr Steven J Hughes;  \n[steven.hughes@surgery.ufl.edu](steven.hughes@surgery.ufl.edu)  \nVariability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer: a systematic review  \nGerik W Tushoski-Alemán  , Alexandra J Crespin, Chibeze J Oguejiofor, Dominique D Szymkiewicz, Kelly M Herremans, Song Han, Steven J Hughes   \nABSTRACT  \nObjectives This systematic review aims to evaluate the methodology used in pancreatic cancer (PC) randomised controlled trials (RCTs) measuring quality of life (QOL) and focuses on the type, frequency, survey compliance and duration of these assessments.  \nDesign Systematic review of PC RCTs measuring QOL. Data sources A search of PubMed.gov and ClinicalTrials. gov was conducted for PC RCTs measuring QOL from inception to 21 March 2023. Only phase III RCTs were included. Studies were excluded if QOL was not measured, the study was phase I/II, in the second-line setting or unavailable in English. Data were independently extracted by two reviewers in a standardised fashion.  \nPrimary and secondary outcome measures Primary outcomes included the type of QOL instrument used, the timing and frequency of assessments, methods of analysis and survey completion rates (SCRs) over time. Secondary outcomes included patient demographics, significant QOL improvements and the frequency of trials measuring QOL.  \nResults Out of 269 studies screened, 54 RCTs were identified, and 24 measured QOL (involving 11 229 patients) . Instruments used included the EORTC QLQ-C30 (n=15), FACT-HEP (n=3), Spitzer-QOL-Index (n=2), EQ- 5D (n=2), LASA (n=1) and FACT-PA (n=1) . Most trials assessed QOL until disease progression or death (10/24), with 4-week intervals being the most common (7/24) . SCRs were reported in 15/24 trials, with disease stage influencing SCRs over time. In trials with metastatic, locally advanced/metastatic, and resectable disease, the median times to reach a 50% response rate—defined as the point where the number of surveys completed was half of the enrolled participants—were 12.41 weeks (n=2), 14.14 weeks (n=10), and 54.2 weeks (n=3), respectively.” Only 2/24 trials reported significant QOL improvements between treatment arms. Patient age was reported in all trials, while race/ethnicity was only reported in 4/24 trials.  \nConclusions Significant variability exists in the timing, methods and reporting of QOL assessments in PC trials. There is a need for further research to assess the implications of missing data and consider the temporality of QOL assessment in patients with advanced cancers and poor prognosis.  \nSTRENGTHS AND LIMITATIONS OF THIS STUDY   \n⇒ This study adheres to Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guidelines and includes all collected data in the supplemental material for improved transparency and reproducibility.  \n⇒ Study methodology related to quality-of-life measurement and assessment in each randomised controlled trial was systematically extracted by two independent reviewers.  \n⇒ Our search strategy was limited to two datab","cbCaicgknCRNsyJj","https://ap.wps.com/l/cbCaicgknCRNsyJj","pdf",1679796,15,"English","# Abstract\n## Objectives and design\n## Data sources and eligibility\n## Outcomes and results\n## Conclusions\n# Strengths and limitations\n# Introduction","[{\"question\":\"What does the systematic review evaluate in pancreatic cancer RCTs?\",\"answer\":\"It evaluates the methodology used to measure quality of life in pancreatic cancer randomized controlled trials, focusing on instrument type, assessment frequency and duration, survey compliance, and reporting practices.\"},{\"question\":\"Which studies were included or excluded?\",\"answer\":\"Only phase III pancreatic cancer RCTs measuring quality of life were included. Studies were excluded if quality of life was not measured, if they were phase I/II, if they were in the second-line setting, or if they were unavailable in English.\"},{\"question\":\"What were the main findings about variability in quality-of-life measurement?\",\"answer\":\"There was significant variability in the timing, methods, and reporting of quality-of-life assessments. Most trials assessed quality of life until disease progression or death, and only a small proportion reported significant quality-of-life improvements between treatment arms.\"}]","Variability of quality-of-life measurements and reporting in randomised controlled trials of pancreatic cancer - a systematic review | PDF",1790036719,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/85ee8f7cbfc7d54dbcce395c8e1645e7.webp",983,1310,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2df5940e194dc86821d269f58de45619.webp",982,1309,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f7e1647a0ec96a465ab3fd84f7bf2b5c.webp",981,1308,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7dc5e4435fcd441de6adcf7591be514c.webp",980,1306]